About Bristol-Myers Squibb (NYSE:BMY)
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.
Industry, Sector and Symbol
Trailing P/E Ratio24.9724409448819
Forward P/E Ratio21.21
Sales & Book Value
Annual Sales$19.43 billion
Price / Sales5.34
Cash Flow$3.13 per share
Price / Cash20.28
Book Value$9.78 per share
Price / Book6.49
Net Income$4.46 billion
Return on Equity22.99%
Return on Assets10.19%
Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions
What is Bristol-Myers Squibb's stock symbol?
Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."
How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?
Bristol-Myers Squibb announced a quarterly dividend on Thursday, December 7th. Investors of record on Friday, January 5th will be given a dividend of $0.40 per share on Thursday, February 1st. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.52%. The ex-dividend date of this dividend is Thursday, January 4th. This is an increase from Bristol-Myers Squibb's previous quarterly dividend of $0.39. View Bristol-Myers Squibb's Dividend History.
How were Bristol-Myers Squibb's earnings last quarter?
Bristol-Myers Squibb Co (NYSE:BMY) announced its earnings results on Thursday, October, 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by $0.02. The biopharmaceutical company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a net margin of 16.29% and a return on equity of 22.99%. The business's revenue for the quarter was up 6.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.77 earnings per share. View Bristol-Myers Squibb's Earnings History.
When will Bristol-Myers Squibb make its next earnings announcement?
What guidance has Bristol-Myers Squibb issued on next quarter's earnings?
Bristol-Myers Squibb issued an update on its FY17 earnings guidance on Thursday, October, 26th. The company provided earnings per share guidance of $2.95-3.05 for the period, compared to the Thomson Reuters consensus estimate of $2.96.
Where is Bristol-Myers Squibb's stock going? Where will Bristol-Myers Squibb's stock price be in 2018?
16 brokerages have issued twelve-month price targets for Bristol-Myers Squibb's stock. Their predictions range from $52.00 to $75.00. On average, they expect Bristol-Myers Squibb's stock price to reach $65.00 in the next year. View Analyst Ratings for Bristol-Myers Squibb.
What are Wall Street analysts saying about Bristol-Myers Squibb stock?
Here are some recent quotes from research analysts about Bristol-Myers Squibb stock:
- 1. According to Zacks Investment Research, "Bristol-Myers’ blockbuster drug Opdivo is facing competitive challenges in the United States. With the FDA approving Merck’s Keytruda, for the first-line treatment of metastatic non-squamous NSCLC, the competition will stiffen up. Pricing concerns, stiff competition in the HCV and immuno-oncology space are expected to remain a significant overhang on the company’s shares. Yervoy’s sales are expected to be under pressure due to adoption of Opdivo in adjuvant melanoma. Gross margin is also expected to be under pressure due to product mix and declines in virology business. Shares of the company have underperformed the industry in the last twelve months. Estimates have remained stable ahead of Q4 earnings. The company has a mixed record of earnings surprises in the recent quarters." (1/19/2018)
- 2. Robert W. Baird analysts commented, "The broader opportunity for 2125, theoretically, is it could be used in many different tumor types and many different cancer indications." (4/25/2017)
- 3. Jefferies Group LLC analysts commented, "Management seems to have scared investors out of the stock by saying they were "committed to" rather than confident on the Opdivo/ Yervoy combo. We see the guidance cut as a casualty of the new era of conservatism at BMY, though the market seems convinced MRK will get KN-021(G) approved by May anyway. We see a potential acquisition of BMY as increasingly likely as the stock moves towards our ex-lung valuation of $44." (1/27/2017)
Who are some of Bristol-Myers Squibb's key competitors?
Some companies that are related to Bristol-Myers Squibb include Merck & Co., Inc. (MRK), Amgen (AMGN), Novo Nordisk A/S (NVO), Sanofi (SNY), Abbott Laboratories (ABT), GlaxoSmithKline (GSK), Eli Lilly and (LLY), AstraZeneca (AZN), Celgene (CELG), GlaxoSmithKline (GSK), Shire (SHPG), Beximco Pharmaceuticals (BXP), Shire (SHP), Teva Pharmaceutical Industries (TEVA), Valeant Pharmaceuticals Intl (VRX), Dr.Reddy's Laboratories (RDY), Catalent (CTLT) and Patheon (PTHN).
Who are Bristol-Myers Squibb's key executives?
Bristol-Myers Squibb's management team includes the folowing people:
- Giovanni Caforio M.D., Chairman of the Board, Chief Executive Officer (Age 52)
- Charles A. Bancroft, Chief Financial Officer and Executive Vice President - Global Business Operations (Age 57)
- Louis S. Schmukler, President - Global Manufacturing and Supply (Age 61)
- Ann Powell Judge, Chief Human Resource Officer, Senior Vice President (Age 51)
- Thomas J. Lynch Jr., M.D., Ph.D., Executive Vice President, Chief Scientific Officer (Age 56)
- Sandra Leung, Executive Vice President, General Counsel (Age 56)
- Murdo Gordon, Executive Vice President, Chief Commercial Officer (Age 50)
- Paul von Autenried, Senior Vice President, Chief Information Officer (Age 55)
- Anne Nielsen, Senior Vice President, Chief Compliance and Ethics Officer (Age 56)
- Joseph C. Caldarella, Senior Vice President, Corporate Controller (Age 61)
Who owns Bristol-Myers Squibb stock?
Bristol-Myers Squibb's stock is owned by a number of of institutional and retail investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.36%), Bank of Montreal Can (0.28%), Hexavest Inc. (0.09%), Chevy Chase Trust Holdings Inc. (0.09%), Strs Ohio (0.09%) and National Pension Service (0.08%). Company insiders that own Bristol-Myers Squibb stock include Autenried Paul Von, Charles A Bancroft, Giovanni Caforio, John E Elicker, Joseph C Caldarella, Lamberto Andreotti, Lewis B Campbell, Louis S Schmukler, Sandra Leung, Theodore R Samuels II and Thomas J Jr Lynch. View Institutional Ownership Trends for Bristol-Myers Squibb.
Who sold Bristol-Myers Squibb stock? Who is selling Bristol-Myers Squibb stock?
Bristol-Myers Squibb's stock was sold by a variety of institutional investors in the last quarter, including First Quadrant L P CA, First Manhattan Co., Strs Ohio, DnB Asset Management AS, Gateway Investment Advisers LLC, Exxonmobil Investment Management Inc. TX, Private Asset Management Inc. and Westpac Banking Corp. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include Joseph C Caldarella, Lamberto Andreotti, Louis S Schmukler, Sandra Leung and Thomas J Jr Lynch. View Insider Buying and Selling for Bristol-Myers Squibb.
Who bought Bristol-Myers Squibb stock? Who is buying Bristol-Myers Squibb stock?
Bristol-Myers Squibb's stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Schwab Charles Investment Management Inc., State of Alaska Department of Revenue, Pensionfund DSM Netherlands, Pensionfund Sabic, Hexavest Inc., Creative Planning and Bredin Investment LLC. View Insider Buying and Selling for Bristol-Myers Squibb.
How do I buy Bristol-Myers Squibb stock?
Shares of Bristol-Myers Squibb can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bristol-Myers Squibb's stock price today?
One share of Bristol-Myers Squibb stock can currently be purchased for approximately $63.43.
How big of a company is Bristol-Myers Squibb?
Bristol-Myers Squibb has a market capitalization of $103.82 billion and generates $19.43 billion in revenue each year. The biopharmaceutical company earns $4.46 billion in net income (profit) each year or $2.54 on an earnings per share basis. Bristol-Myers Squibb employs 25,000 workers across the globe.
How can I contact Bristol-Myers Squibb?
Bristol-Myers Squibb's mailing address is 345 PARK AVE, NEW YORK, NY 10154, United States. The biopharmaceutical company can be reached via phone at +1-212-5464000 or via email at [email protected]
MarketBeat Community Rating for Bristol-Myers Squibb (BMY)MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Bristol-Myers Squibb (NYSE:BMY) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Hold|
|Consensus Rating Score: ||2.44||2.44||2.41||2.43|
|Ratings Breakdown: ||1 Sell Rating(s)|
7 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
8 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
8 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
10 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$65.00||$63.92||$63.69||$63.00|
|Price Target Upside: ||2.72% upside||2.41% upside||0.48% downside||13.99% upside|
Bristol-Myers Squibb (NYSE:BMY) Consensus Price Target History
Bristol-Myers Squibb (NYSE:BMY) Analyst Ratings History
(Data available from 1/24/2016 forward)
Bristol-Myers Squibb (NYSE:BMY) Earnings History and Estimates Chart
Bristol-Myers Squibb (NYSE BMY) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/26/2017||Q3 2017||$0.77||$0.75||$5.20 billion||$5.25 billion||View||N/A|
|7/27/2017||Q2 2017||$0.73||$0.74||$5.09 billion||$5.14 billion||View||N/A|
|4/27/2017||Q1 2017||$0.72||$0.84||$4.75 billion||$4.93 billion||View||N/A|
|1/26/2017||Q416||$0.67||$0.63||$5.14 billion||$5.24 billion||View||N/A|
|10/27/2016||Q316||$0.65||$0.77||$4.76 billion||$4.83 billion||View||Listen|
|7/28/2016||Q216||$0.67||$0.69||$4.60 billion||$4.90 billion||View||Listen|
|4/28/2016||Q116||$0.65||$0.74||$4.19 billion||$4.39 billion||View||Listen|
|1/28/2016||Q415||$0.28||$0.38||$4.07 billion||$4.29 billion||View||Listen|
|10/27/2015||Q315||$0.35||$0.39||$3.83 billion||$4.07 billion||View||Listen|
|7/23/2015||Q215||$0.36||$0.53||$3.68 billion||$4.16 billion||View||Listen|
|4/28/2015||Q115||$0.50||$0.71||$3.80 billion||$4.04 billion||View||N/A|
|1/27/2015||Q414||$0.40||$0.46||$4.02 billion||$4.26 billion||View||N/A|
|10/24/2014||Q314||$0.42||$0.45||$3.80 billion||$3.92 billion||View||Listen|
|7/24/2014||Q214||$0.44||$0.48||$3.85 billion||$3.89 billion||View||Listen|
|4/29/2014||Q114||$0.43||$0.46||$3.89 billion||$3.81 billion||View||Listen|
|1/24/2014||Q413||$0.43||$0.53||$4.30 billion||$4.44 billion||View||Listen|
|10/23/2013||Q313||$0.44||$0.46||$4.02 billion||$4.07 billion||View||Listen|
|7/25/2013||Q2 2013||$0.45||$0.44||$4.07 billion||$4.05 billion||View||Listen|
|4/25/2013||Q1 2013||$0.41||$0.41||$3.88 billion||$3.83 billion||View||Listen|
|1/24/2013||Q4 2012||$0.42||$0.47||$4.14 billion||$4.19 billion||View||Listen|
Bristol-Myers Squibb (NYSE:BMY) Earnings Estimates
2018 EPS Consensus Estimate: $3.08
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Bristol-Myers Squibb (NYSE:BMY) Dividend Information
|Dividend Growth:||2.70% (3 Year Average)|
|Payout Ratio:||62.99% (Trailing 12 Months of Earnings) |
53.51% (Based on This Year's Estimates)
50.00% (Based on Next Year's Estimates)
|Track Record:||8 Years of Consecutive Dividend Growth|
Bristol-Myers Squibb (NYSE:BMY) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Bristol-Myers Squibb (NYSE BMY) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 69.75%
Bristol-Myers Squibb (NYSE BMY) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/15/2017||Theodore R Samuels II||Director||Buy||4,000||$62.30||$249,200.00||22,000|| |
|12/12/2017||Thomas J Jr. Lynch||EVP||Sell||5,300||$63.24||$335,172.00||9,251|| |
|12/4/2017||Sandra Leung||EVP||Sell||156,582||$63.37||$9,922,601.34||584,373|| |
|9/6/2017||Joseph C Caldarella||SVP||Sell||9,340||$60.00||$560,400.00||46,297|| |
|8/2/2017||Theodore R Samuels II||Director||Buy||6,000||$55.94||$335,640.00||18,000|| |
|4/7/2017||Lamberto Andreotti||Director||Sell||34,000||$53.26||$1,810,840.00||952,571|| |
|3/28/2017||Lamberto Andreotti||Director||Sell||34,000||$56.17||$1,909,780.00||986,112|| |
|3/27/2017||Lamberto Andreotti||Director||Sell||17,000||$56.14||$954,380.00||986,112|| |
|3/17/2017||Louis S Schmukler||Insider||Sell||5,000||$56.49||$282,450.00||21,483|| |
|3/15/2017||Joseph C Caldarella||SVP||Sell||8,096||$57.29||$463,819.84||55,637|| |
|3/6/2017||Sandra Leung||EVP||Sell||92,405||$57.02||$5,268,933.10||488,063|| |
|2/27/2017||Theodore R Samuels II||Director||Buy||12,000||$56.77||$681,240.00||12,000|| |
|9/8/2016||Lamberto Andreotti||Director||Sell||21,600||$56.87||$1,228,392.00||334,499|| |
|8/25/2016||Lamberto Andreotti||Director||Sell||23,200||$59.17||$1,372,744.00||364,999|| |
|7/8/2016||Lamberto Andreotti||Director||Sell||23,200||$74.45||$1,727,240.00||380,099|| |
|6/28/2016||Lamberto Andreotti||Director||Sell||23,200||$72.14||$1,673,648.00||403,094|| |
|6/14/2016||John E Elicker||SVP||Sell||11,820||$72.69||$859,195.80||55,011|| |
|5/20/2016||Charles A Bancroft||CFO||Sell||30,201||$70.79||$2,137,928.79||184,694|| |
|5/16/2016||Joseph C Caldarella||SVP||Sell||3,519||$72.47||$255,021.93||55,238|| |
|5/6/2016||Sandra Leung||EVP||Sell||72,544||$70.39||$5,106,372.16||444,507|| |
|5/5/2016||Lamberto Andreotti||Director||Sell||23,200||$70.54||$1,636,528.00||425,194|| |
|5/3/2016||Giovanni Caforio||CEO||Sell||34,594||$71.31||$2,466,898.14||132,263|| |
|5/2/2016||Autenried Paul Von||SVP||Sell||37,258||$71.93||$2,679,967.94||128,463|| |
|5/2/2016||Lamberto Andreotti||Director||Sell||234,720||$71.88||$16,871,673.60||536,794|| |
|5/2/2016||Louis S Schmukler||Insider||Sell||22,218||$71.95||$1,598,585.10||21,971|| |
|4/5/2016||Lamberto Andreotti||Director||Sell||23,200||$65.90||$1,528,880.00||453,094|| |
|4/4/2016||Lamberto Andreotti||Director||Sell||11,600||$65.79||$763,164.00||453,094|| |
|3/9/2016||Lamberto Andreotti||Director||Sell||23,200||$65.71||$1,524,472.00||381,254|| |
|3/8/2016||Lewis B Campbell||Director||Sell||2,500||$66.00||$165,000.00||2,500|| |
|3/4/2016||Joseph C Caldarella||SVP||Sell||12,962||$64.64||$837,863.68||46,322|| |
|2/17/2016||Giovanni Caforio||CEO||Sell||12,040||$63.58||$765,503.20||76,738|| |
|2/17/2016||Sandra Leung||EVP||Sell||10,152||$63.57||$645,362.64||309,547|| |
|2/12/2016||Lamberto Andreotti||Director||Sell||23,200||$59.61||$1,382,952.00||392,854|| |
|1/5/2016||Lamberto Andreotti||Director||Sell||23,200||$67.56||$1,567,392.00||310,424|| |
|1/4/2016||Lamberto Andreotti||Director||Sell||11,600||$66.93||$776,388.00||310,424|| |
|12/15/2015||Lamberto Andreotti||Director||Sell||23,200||$69.03||$1,601,496.00||332,852|| |
|11/20/2015||Lamberto Andreotti||Director||Sell||23,200||$67.39||$1,563,448.00||456,052|| |
|10/6/2015||Lamberto Andreotti||Director||Sell||23,200||$60.86||$1,411,952.00||524,252|| |
|9/3/2015||Lamberto Andreotti||Director||Sell||23,200||$59.40||$1,378,080.00||546,874|| |
|6/4/2015||Joseph C Caldarella||SVP||Sell||16,972||$65.71||$1,115,230.12|| |
|3/16/2015||Francis M Cuss||EVP||Sell||114,666||$67.81||$7,775,501.46|| |
|3/16/2015||Louis S Schmukler||Insider||Sell||12,000||$66.96||$803,520.00|| |
|2/17/2015||Sandra Leung||General Counsel||Sell||11,746||$60.39||$709,340.94|| |
|2/12/2015||Samuel J Moed||SVP||Sell||3,880||$59.26||$229,928.80|| |
|2/6/2015||Samuel J Moed||SVP||Sell||21,478||$60.15||$1,291,901.70|| |
|1/29/2015||Lamberto Andreotti||CEO||Sell||90,246||$61.14||$5,517,640.44|| |
|1/29/2015||Lewis B Campbell||Director||Sell||2,500||$60.89||$152,225.00|| |
|1/29/2015||Louis S Schmukler||Insider||Sell||5,250||$60.73||$318,832.50|| |
|12/5/2014||Lamberto Andreotti||CEO||Sell||75,000||$60.31||$4,523,250.00|| |
|10/24/2014||Lamberto Andreotti||CEO||Sell||50,000||$53.00||$2,650,000.00|| |
|10/6/2014||Lamberto Andreotti||CEO||Sell||50,000||$50.99||$2,549,500.00|| |
|9/16/2014||Francis M Cuss||EVP||Sell||63,667||$50.77||$3,232,373.59|| |
|9/15/2014||Giovanni Caforio||COO||Sell||26,691||$49.87||$1,331,080.17|| |
|9/10/2014||Joseph C Caldarella||SVP||Sell||7,415||$51.03||$378,387.45|| |
|9/8/2014||Lamberto Andreotti||CEO||Sell||50,000||$51.05||$2,552,500.00|| |
|8/19/2014||Autenried Paul Von||SVP||Sell||20,000||$49.89||$997,800.00|| |
|7/29/2014||Charles A Bancroft||CFO||Sell||67,621||$51.06||$3,452,728.26|| |
|7/28/2014||Samuel J Moed||SVP||Sell||25,752||$49.32||$1,270,088.64|| |
|3/13/2014||Joseph Caldarella||SVP||Sell||9,137||$55.20||$504,362.40||68,965|| |
|3/10/2014||Lamberto Andreotti||CEO||Sell||100,000||$55.52||$5,552,000.00||630,783|| |
|3/10/2014||Louis Schmukler||Insider||Sell||8,799||$55.81||$491,072.19||8,861|| |
|3/5/2014||James Cornelius||Director||Sell||100,000||$55.82||$5,582,000.00||273,393|| |
|2/28/2014||Louis Schmukler||Insider||Sell||6,088||$54.49||$331,735.12||14,696|| |
|2/24/2014||Giovanni Caforio||EVP||Sell||41,563||$54.44||$2,262,689.72||49,753|| |
|2/19/2014||John Elicker||SVP||Sell||9,534||$54.22||$516,933.48||32,740|| |
|2/18/2014||Francis Cuss||EVP||Sell||29,800||$54.61||$1,627,378.00||207,237|| |
|2/14/2014||Charles Bancroft||CFO||Sell||52,963||$54.35||$2,878,539.05||77,303|| |
|2/14/2014||Sandra Leung||General Counsel||Sell||10,490||$54.28||$569,397.20||195,855|| |
|2/11/2014||Lamberto Andreotti||CEO||Sell||86,075||$52.66||$4,532,709.50||500,487|| |
|2/6/2014||Joseph Caldarella||SVP||Sell||35,471||$48.90||$1,734,531.90||59,355|| |
|2/5/2014||Lewis Campbell||Director||Sell||2,500||$48.28||$120,700.00|| |
|2/4/2014||James Cornelius||Director||Sell||100,000||$48.90||$4,890,000.00||373,393|| |
|7/29/2013||James M Cornelius||Director||Sell||5,000||$43.81||$219,050.00|| |
|6/10/2013||Autenried Paul Von||SVP||Sell||25,000||$47.24||$1,181,000.00|| |
|6/6/2013||Joseph C Caldarella||SVP||Sell||26,275||$46.53||$1,222,575.75|| |
|6/5/2013||John E Elicker||SVP||Sell||25,997||$46.33||$1,204,441.01|| |
|6/4/2013||Lamberto Andreotti||CEO||Sell||100,000||$47.74||$4,774,000.00|| |
|6/4/2013||Samuel J Moed||SVP||Sell||58,898||$47.38||$2,790,587.24|| |
|6/3/2013||Elliot Sigal||EVP||Sell||83,647||$48.18||$4,030,112.46|| |
|5/31/2013||Beatrice J Cazala||EVP||Sell||91,282||$47.00||$4,290,254.00|| |
|5/31/2013||Giovanni Caforio||Insider||Sell||10,538||$47.06||$495,918.28|| |
|5/30/2013||Beatrice J Cazala||EVP||Sell||22,000||$47.00||$1,034,000.00|| |
|5/28/2013||Charles A Bancroft||CFO||Sell||25,000||$48.68||$1,217,000.00|| |
|5/28/2013||James M Cornelius||Director||Sell||100,000||$47.61||$4,761,000.00|| |
|5/23/2013||Beatrice J Cazala||EVP||Sell||96,000||$46.99||$4,511,040.00|| |
|5/23/2013||Giovanni Caforio||Insider||Sell||26,647||$46.29||$1,233,489.63|| |
|5/17/2013||James M Cornelius||Director||Sell||225,996||$42.99||$9,715,568.04|| |
|5/8/2013||James M Cornelius||Director||Sell||20,000||$39.85||$797,000.00|| |
|5/2/2013||James M Cornelius||Director||Sell||20,000||$39.76||$795,200.00|| |
|4/11/2013||James M Cornelius||Director||Sell||20,000||$41.15||$823,000.00|| |
|3/13/2013||James M Cornelius||Director||Sell||20,000||$38.18||$763,600.00|| |
|3/13/2013||John E Elicker||SVP||Sell||3,409||$38.51||$131,280.59|| |
|2/27/2013||Giovanni Caforio||Insider||Sell||12,150||$37.08||$450,522.00|| |
|2/26/2013||James M Cornelius||Director||Sell||20,000||$36.58||$731,600.00|| |
|1/17/2013||James M Cornelius||Director||Sell||20,000||$34.33||$686,600.00|| |
|12/28/2012||James M Cornelius||Director||Sell||20,000||$32.06||$641,200.00|| |
|10/3/2012||James M Cornelius||Director||Sell||20,000||$33.71||$674,200.00|| |
|8/10/2012||James M Cornelius||Director||Sell||10,000||$31.81||$318,100.00|| |
Bristol-Myers Squibb (NYSE BMY) News Headlines
Bristol-Myers Squibb (NYSE:BMY) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Bristol-Myers Squibb (NYSE:BMY) Income Statement, Balance Sheet and Cash Flow Statement
Bristol-Myers Squibb (NYSE BMY) Stock Chart for Wednesday, January, 24, 2018